亞洲知識產權資訊網為知識產權業界提供一個一站式網上交易平台,協助業界發掘知識產權貿易商機,並與環球知識產權業界建立聯繫。無論你是知識產權擁有者正在出售您的知識產權,或是製造商需要購買技術以提高操作效能,又或是知識產權配套服務供應商,你將會從本網站發掘到有用的知識產權貿易資訊。

New Drugs for Malaria and Bacterial Infections

詳細技術說明
New anti-infectives are required now more than ever as resistance to existing drugs increases in prevalence. This pathway is not present in humans and thus is an excellent target for new anti-infective drugs.
*Abstract

New anti-infectives are required now more than ever as resistance to existing drugs increases in prevalence. Enzymes unique to bacteria or parasites are potential drug targets with minimal side effects because they are not present in humans. One such source of potential drug targets is the isoprenoid biosynthesis pathway. Many pathogenic bacteria and malaria parasites use isoprenoids in their cell walls, to protect against the human immune system, and for other functions. This pathway is not present in humans and thus is an excellent target for new anti-infective drugs. 

Scientists from the University of Illinois at Urbana-Champaigns Departments of Chemistry and Biophysics have identified a class of novel chemical entities that are capable of inhibiting two key enzymes, GcpE and LytB, in the isoprenoid biosynthesis pathway. These compounds are able to inhibit the isoprenoid biosynthetic pathway at concentrations far lower than any other known inhibitors and have the potential to treat a wide-range of infectious disease caused by both bacteria and malarial parasites. In addition, it may be possible to use these compounds for the treatment of cancers, via immune system activation. 

DESCRIPTION/DETAILS 

This invention includes a class of novel chemical entities composed of similar geometries and bonds. They inhibit through a unique organometallicinteraction that has not been previously described. 

APPLICATIONS

Currently, the compounds are being evaluated for their ability to act as:o Broad spectrum anti-infectiveso Cytotoxic cancer drugsOther compounds produced using similar chemistry may have a wide range of medical applications 

BENEFITS

  • Novel Mechanism: These compounds act on the isoprenoid pathway using a chemical interaction that has not been previously described. Continued work on these compounds is designed to identify new applications of this interaction, beyond anti-infectives.

For more information about this technology, please contact the University of Illinois at Urbana-Champaign Office of Technology Management at otm@illinois.edu.

*IP Issue Date
None
*IP Type
Utility
國家
United States
申請號碼
8609638
國家/地區
美國

欲了解更多信息,請點擊 這裡
移動設備